The Liquid Biopsy Market is strongly influenced by oncology applications, where demand for advanced molecular diagnostics continues to expand. According to WiseGuyReports, oncology represented the largest application segment, with a market value of approximately USD 6 billion in 2024 and a projected value of USD 18 billion by 2035.

Cancer-related applications are driving interest in liquid biopsy because these technologies can provide molecular information from biological samples. Their potential use across cancer detection, monitoring, and molecular profiling is encouraging diagnostic companies and research organizations to develop increasingly sophisticated testing platforms.

The market extends beyond oncology. Prenatal testing, infectious diseases, and transplantation are also included within the application landscape. Prenatal testing is benefiting from advances in non-invasive testing technologies, while research into infectious disease and transplantation applications is contributing to broader market diversification.

Circulating tumor DNA is another important area of market development. The report identifies ctDNA as a segment expected to experience strong growth because of its potential applications in treatment-response monitoring and minimal residual disease detection. Continued biomarker research could further expand the range of applications supported by liquid biopsy technologies.

As oncology research increasingly incorporates molecular information, opportunities are emerging for diagnostic laboratories, biotechnology companies, and technology providers. Future growth will depend on continued innovation, clinical integration, regulatory development, and the expansion of liquid biopsy applications across different disease areas.